Phase 2 Huntington's Disease Trial, Recruiting NCT07451613 Sponsor: Leslie Thompson Condition: Huntington's Disease
Back to Huntingtons Disease

Phase 2 Huntington's Disease Trial, Recruiting

NCT07451613
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to make your own decisions and are willing to sign a written consent form to take part.
  • You are between 18 and 65 years old.
  • You have been diagnosed with Huntington's Disease confirmed through genetic testing.
  • You are able to have MRI scans, tolerate a brain surgery procedure, blood tests, and a lumbar puncture (a needle procedure to collect fluid from your lower back).

Who may not be able to join:

  • You are currently pregnant.
  • You tested positive for HIV, hepatitis C, or long-term (chronic) hepatitis B during the screening process.
  • You already have a deep brain stimulation device implanted in your body (a surgically placed device that sends electrical signals to the brain).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 949-824-3990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Leslie Thompson
Registry
ClinicalTrials.gov
Start date
6 April 2026
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 after 6 and 12 weeks after dosing.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov